Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes

ClinicalTrials.gov ID: NCT03292016

Public ClinicalTrials.gov record NCT03292016. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study that compares the extent to which apomorphine becomes available in the body after taking either an investigational drug containing apomorphine or apomorphine that is injected under the skin in people with PD complicated by "OFF" episodes.

Study identification

NCT ID
NCT03292016
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Enrollment
8 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 21, 2017
Primary completion
Mar 4, 2019
Completion
Mar 4, 2019
Last update posted
Aug 12, 2020

2017 – 2019

United States locations

U.S. sites
3
U.S. states
2
U.S. cities
3
Facility City State ZIP Site status
Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida 33486
Parkinson's Disese Treatment Center of SW Florida Port Charlotte Florida 33980
QUEST Research Institute Farmington Hills Michigan 48334

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Parkinson Disease trials

Other public records listing Parkinson Disease. Sorted by last update posted; newest first. Not a recommendation.

All Parkinson Disease trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03292016, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 12, 2020 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03292016 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →